摘要
【目的】探讨新辅助化疗对乳腺癌患者血清胰岛素样生长因子-1(IGF-1)水平的影响。【方法】70例乳腺癌患者均接受术前新辅助化疗,同时随机选择20例乳腺良性疾病患者纳入乳腺良性疾病组,20例健康体检者纳入对照组。记录乳腺癌患者新辅助化疗疗效及比较各组研究对象血清IGF-1水平。【结果】乳腺癌组患者血清IGF_1水平明显高于对照组及乳腺良性疾病组,且差异均有显著性(P〈0.05);血清IGF-1水平在年龄≥45岁、临床分期Ⅲ-Ⅳ期、有淋巴结转移及雌激素受体ER阳性的乳腺癌患者中明显升高,且差异有显著性(P〈0.05);乳腺癌患者治疗有效率为71.43%(50/70),血清IGF-1水平在化疗后较化疗前明显降低,且差异有显著性[(168.6±33.4)ng/mLVS(125.3±29.5)ng/mL,P〈0.05]。【结论】乳腺癌患者血清IGF-1水平显著增高,新辅助化疗可抑制乳腺癌患者IGF-1的生成,进而抑制体内肿瘤细胞的增殖。
[Objeetive]To investigate the effects of neoadjuvant chemotherapy on serum insulin-like growth fac- tor-1 (IGF-1) in patients with breast cancer. [Methods]Seventy patients with breast cancer were treated with neoad- juvant chemotherapy before receiving surgery. At the same time 20 patients with benign breast disease were enrolled in the benign disease group, and 20 healthy patients were enrolled in the control group. The clinical effects of neoadju- rant chemotherapy in the 70 breast cancer patients were analyzed, and the differences in serum IGF-1 levels between the groups were recorded. [Results] The serum IGF-1 levels in the breast cancer group were significantly higher than in the control and benign disease group, and the differences were statistically significant (P 〈 0.05). The serum IGF- 1 levels in breast cancer patients of ≥ 45 years, clinical stage Ⅲ-Ⅳ stage, lymph node metastasis, and estrogen re- ceptor ER ( + ) were significantly higher than breast cancer patients who did not satisfy the conditions. The difference was statistically significant ( P〈0.05). The effective treatment rate in the 70 cases of patients with breast cancer was 71.43%, and after chemotherapy treatment, the serum IGF 1 levels significantly decreased ( P 〈0.05). [Conclu- sion] Serum IGF-1 level is high in patients with breast cancer, but neoadjuvant chemotherapy can inhibit the forma- tion of IGF-1 in patients with breast cancer as well as inhibit the proliferation of tumor cells.
出处
《医学临床研究》
CAS
2016年第5期928-929,932,共3页
Journal of Clinical Research